---
title: "FOXO4-DRI"
canonical_url: https://peptidelibrary.app/library/foxo4-dri
description: "D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# FOXO4-DRI

FOXO4-DRI (also called Proxofim or FOXO4-D-Retro-Inverso) is a senolytic FOXO4 peptide. FOXO4-DRI is a retro-inverso peptide — built from D-amino acids in reversed sequence — modelled on the FOXO4 region that binds p53. In senescent cells FOXO4 sequesters p53 in the nucleus, preventing it from initiating apoptosis and allowing those cells to persist despite accumulated damage.

D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.

Also known as: Proxofim, FOXO4-D-Retro-Inverso, FOXO4 p53 disruptor.

Categories: Longevity, Experimental.

## Classification

- Type: Senolytic FOXO4 peptide / research
- Mechanism class: Senolytic peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

FOXO4-DRI is a retro-inverso peptide — built from D-amino acids in reversed sequence — modelled on the FOXO4 region that binds p53. In senescent cells FOXO4 sequesters p53 in the nucleus, preventing it from initiating apoptosis and allowing those cells to persist despite accumulated damage. The peptide competes for that interaction, releasing p53 to translocate to the mitochondria and trigger apoptosis. Because the FOXO4-p53 interaction is markedly more important in senescent than in healthy cells, the effect is relatively selective for senescent fibroblasts, which is what makes it a senolytic. The retro-inverso construction confers protease resistance. Evidence comes from the original mouse work; there are no human trials.

Targets: FOXO4–p53 interaction.

Origin: Synthetic D-retro-inverso peptide (Baar et al., Cell 2017).

## Properties

- Molecular formula: C228H388N86O64
- Molecular weight: 5,358 g/mol
- CAS number: 2460055-10-9
- Half-life: Experimental; not established

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 4
- Latest source: 2023

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017. 2017. Preclinical: in vitro (cells or tissue). Population: Mice given doxorubicin, fast-ageing XpdTTD/TTD mice and naturally aged mice. Countered doxorubicin toxicity and restored fitness, fur density and kidney function in the ageing mice. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/28340339/)
2. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020. 2020. Preclinical: in vitro (cells or tissue). Population: Naturally aged mice; senescent TM3 Leydig cells in culture. Apoptosis of senescent Leydig cells in culture, and a better testicular environment with less age-related shortfall in testosterone in the mice. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/31959736/)
3. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2023. 2023. Preclinical: in vitro (cells or tissue). Population: Mice with bleomycin-induced pulmonary fibrosis; activated fibroblasts in culture. Milder lung changes and less collagen deposition than in the untreated model group. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/37074394/)
4. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021. 2021. Preclinical: in vitro (cells or tissue). Population: Chondrocytes from healthy human donors, expanded in the laboratory. Removed more than half of the heavily expanded cells and lowered senescence markers, but did not improve their ability to form cartilage. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/33996787/)

## Safety

Side effects: No established human dose; On-target p53 risks theoretical.

Risks: WADA S0 likely (non-approved); Preclinical only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

FOXO4-DRI is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is FOXO4-DRI?

D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.

### How does FOXO4-DRI work?

FOXO4-DRI is a retro-inverso peptide — built from D-amino acids in reversed sequence — modelled on the FOXO4 region that binds p53. In senescent cells FOXO4 sequesters p53 in the nucleus, preventing it from initiating apoptosis and allowing those cells to persist despite accumulated damage.

### Is FOXO4-DRI FDA approved?

No. FOXO4-DRI is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of FOXO4-DRI?

Reported half-life for FOXO4-DRI is Experimental; not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is FOXO4-DRI banned in sport?

FOXO4-DRI is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to FOXO4-DRI?

Compounds most often compared with FOXO4-DRI include Epitalon, Pinealon, Klotho and NAD+ (Nicotinamide Adenine Dinucleotide). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nat Commun, 2025](https://pubmed.ncbi.nlm.nih.gov/40593617/)
- [FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway — Front Bioeng Biotechnol, 2025](https://pubmed.ncbi.nlm.nih.gov/41625068/)
- [FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Commun Biol, 2025](https://pubmed.ncbi.nlm.nih.gov/39994346/)
- [FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells — Exp Gerontol, 2024](https://pubmed.ncbi.nlm.nih.gov/39025385/)
- [FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice — Naunyn Schmiedebergs Arch Pharmacol, 2023](https://pubmed.ncbi.nlm.nih.gov/37074394/)
